Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Ferner

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
British Journal of Clinical Pharmacology|October 19, 2019
Drug and therapeutics committees as guardians of safe and rational medicines useReecha Sofat, Serge Cremers, R E Ferner
Neurofibromatosis|January 1, 1989
Spinal neurofibroma presenting as atlanto-axial subluxation in von Recklinghausen neurofibromatosisR E Ferner, M Honavar, R W Gullan
British Journal of Clinical Pharmacology|January 1, 1993
Paracetamol elimination in patients with non-insulin dependent diabetes mellitusF Kamali, S H Thomas, R E Ferner
British Journal of Clinical Pharmacology|January 1, 1991
The effects of enalapril and sulindac on the dermal response to substance P and neurokinin AR E Ferner, F Kamali, M D Rawlins
Eye (London, England)|January 29, 2011
Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1D H Gutmann, R Listernick, R E Ferner
Human & Experimental Toxicology|May 1, 1994
A radiographic lead in lead poisoningM Kulshrestha, S E Newey, R E Ferner
Lancet (London, England)|February 15, 1986
Tri-iodothyroacetic acid abuse in a female body builderR E Ferner, A Burnett, M D Rawlins
BMJ (Clinical Research Ed.)|June 3, 2010
Controversy over generic substitutionR E Ferner, Warren Lenney, John F Marriott
Lancet (London, England)|August 13, 1988
Safety of mianserinD N Bateman, S Chaplin, R E Ferner
BMJ (Clinical Research Ed.)|December 22, 1999
The lacing defence: double blind study of thresholds for detecting addition of ethanol to drinksN J Langford, T Marshall, R E Ferner
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
British Journal of Clinical Pharmacology|October 19, 2019
Drug and therapeutics committees as guardians of safe and rational medicines useReecha Sofat, Serge Cremers, R E Ferner
Neurofibromatosis|January 1, 1989
Spinal neurofibroma presenting as atlanto-axial subluxation in von Recklinghausen neurofibromatosisR E Ferner, M Honavar, R W Gullan
British Journal of Clinical Pharmacology|January 1, 1993
Paracetamol elimination in patients with non-insulin dependent diabetes mellitusF Kamali, S H Thomas, R E Ferner
British Journal of Clinical Pharmacology|January 1, 1991
The effects of enalapril and sulindac on the dermal response to substance P and neurokinin AR E Ferner, F Kamali, M D Rawlins
Eye (London, England)|January 29, 2011
Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1D H Gutmann, R Listernick, R E Ferner
Human & Experimental Toxicology|May 1, 1994
A radiographic lead in lead poisoningM Kulshrestha, S E Newey, R E Ferner
Lancet (London, England)|February 15, 1986
Tri-iodothyroacetic acid abuse in a female body builderR E Ferner, A Burnett, M D Rawlins
BMJ (Clinical Research Ed.)|June 3, 2010
Controversy over generic substitutionR E Ferner, Warren Lenney, John F Marriott
Lancet (London, England)|August 13, 1988
Safety of mianserinD N Bateman, S Chaplin, R E Ferner
BMJ (Clinical Research Ed.)|December 22, 1999
The lacing defence: double blind study of thresholds for detecting addition of ethanol to drinksN J Langford, T Marshall, R E Ferner
Pageof 15